Laura Alder, Medical Oncology Deputy Director at Duke Center for Brain and Spine Metastasis, shared on LinkedIn:
“Join us on Nov 14th, 2026 in Charlotte, NC for ‘Bispecifics, ADCs and Beyond: Challenges and Strategies in Clinical Implementation’ hosted by Duke Cancer Network and Duke Cancer Institute.
I’m honored to serve as co-chair of this conference and am delighted to welcome our keynote speaker, Charles Rudin, of Memorial Sloan Kettering Cancer Center, presenting on novel approaches to immunotherapy in small cell lung cancer.
Bispecific antibodies and antibody-drug conjugates are moving quickly from clinical trials into everyday practice, and the practical questions are piling up. How do we manage step-up dosing and CRS outside an academic center?
Who monitors for ICANS and other CNS complications? What does ocular, pulmonary, or hematologic toxicity surveillance actually look like in a busy community clinic?
The program is built for the whole care team – oncologists, advanced practice providers, nurses, and pharmacists – with a deliberate focus on real-world implementation: clinical advances in bispecifics and ADCs across solid tumors, toxicity management, CNS complications, and the operational realities of delivering these therapies in the community setting.”
